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doi:10.1016/j.jfma.2011.06.025Background/Purpose: Immune thrombocytopenia (ITP) is a heterogeneous autoimmune
disorder with diverse response rates to treatments that include corticosteroids, intravenous
immunoglobulins (IVIG), and splenectomy. The predisposing causes of this autoimmune
disorder, one of which is immunogenetic susceptibility, have not been fully determined. We
investigated whether clinical features and human leukocyte antigen (HLA) genotypes influence
the occurrence, treatment response, and disease duration of childhood ITP in Taiwan.
Methods: We performed HLA genotyping of 70 Taiwanese children with ITP and of 70 healthy
controls and compared the data. Demographic data were also collected and evaluated.
Results: The frequencies of heterozygous HLA-A11 and the HLA-Cw1 allele were both signifi-
cantly decreased in the ITP group (p Z 0.0160 and p Z 0.0089, respectively), whereas the
frequency of heterozygous HLA-DQ5 was significantly increased in the ITP group
(p Z 0.0057). Patients with HLA-DRB1*11 or -DRB1*15 were more likely to respond poorly to
corticosteroids than IVIG (pZ 0.0446 and pZ 0.0008, respectively). In addition, we observed
a positive association between HLA-A11 homozygosity and the development of persistent or
chronic ITP [odds ratio (OR) Z 6.3165, p Z 0.0479]. The presence of HLA-DRB1*08 was,
however, negatively correlated with the development of persistent or chronic ITPematology/Oncology, Department of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan
edu.tw (W.-L. Ho), khlin2@ntu.edu.tw (K.-H. Lin).
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MHC and pediatric ITP 371(OR Z 0.1729, p Z 0.0657). Children with antecedent of preceding illness (API) and with
a younger age of onset were more likely to experience a better treatment response and shorter
course of ITP.
Conclusion: We suggest that API, age of onset, and particular HLA class I and class II alleles,
may be involved in and influence the occurrence and disease duration of childhood ITP, as well
as responses to different therapeutic approaches.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Immune thrombocytopenia (ITP) is a heterogeneous disease
characterized by increased platelet destruction and
thrombocytopenia. Most researchers believe that this
platelet destruction is immune mediated and may also
involve the inhibition of platelet release by megakaryo-
cytes. Autoantibodies against platelet antigens are the
diagnostic hallmark of ITP; however, this mechanism may
not account for all cases, as antiplatelet autoantibodies are
detected in only 50%e70% of patients with ITP.1e4 Failure to
detect autoantibodies could be due to limited test sensi-
tivity, undetected antigens, or additional mechanisms of
platelet loss. Other contributing mechanisms for ITP have
been proposed, such as complement-mediated lysis,5
tolerance checkpoint defects, ineffective thrombopoiesis,
direct T-cell cytotoxicity, and a combination of genetic
susceptibility and environmental factors.3
The functional role of human leukocyte antigen (HLA),
which is the human form of the major histocompatibility
complex (MHC), is to present antigens to the immune system,
and the genetic diversity of the HLA is postulated to have
arisen as a host strategy to counter the antigenic diversity of
infectious organisms. To identify potential susceptibility
factors for ITP, several groups have focused on the identifi-
cation of MHC genes; however, findings from these HLA
association studies in ITP have produced inconsistent results.
Nomura and colleagues6 examined the clinical significance of
HLA class II genes in more than 100 Japanese patients with
ITP and showed that the frequency of the DRB1*0410 allele
was significantly increased in patients with ITP compared
with controls. Moreover, this allele was found significantly
less frequently in patients who showed a good response to
prednisolone. Stanworth and others7 reported an association
between the presence of HLA-A2 and ITP, particularly in
female patients, with HLA-A2 also present at increased
frequency in patients with chronic ITP that progressed to
requiring splenectomy. Another study revealed strong asso-
ciations between anti-glycoprotein autoantibodies and HLA
class II alleles: antibodies against GPIIb-IIIa were associated
with DRB1*0405 and DQB1*0401, and antibodies against GPIb-
IX were associated with DRB1*0803 and DQB1*0601.8 When
factors influencing therapeutic responses to splenectomy
were examined, a poor response was correlated with the
presence of DRB1*0405, DQB1*0401, and antieGPIIb-IIIa.
Furthermore, some groups have reported weak associations,
such as an increased frequency of HLA-Bw56 and HLA-DR2, in
patients with ITP.9,10
Based on these previous studies and two additional
aspects of ITP, we hypothesized that the HLA class I genes
(in addition to the HLA class II genes) may play critical roles
in childhood ITP. First, the platelet surface expresses HLAclass I molecules (rather than HLA class II molecules), but
platelet interactions with cytotoxic T cells, natural killer
(NK) cells, and killer cell immunoglobulin-like receptors
(KIRs) in patients with ITP are not well understood. Second,
it is commonly accepted that childhood ITP is associated
with infection, either viral or bacterial.11 Thus, to investi-
gate whether HLA classes I and II genotypes play a critical
role in childhood ITP in Taiwan, we first identified demo-
graphic factors, laboratory parameters, and other clinical
characteristics that may be linked to the course and
treatment responses of childhood ITP. We performed HLA
class I (HLA-A, -B, and -C) and class II (HLA-DQ and -DR)
genotyping to explore the relationship between HLA
susceptibility genes and the occurrence, treatment
responses, and disease duration of childhood ITP in Taiwan.Materials and methods
Participants
Patients were identified following a retrospective review of
medical records at National Taiwan University Hospital and
Shin Kong Wu Ho-Su Memorial Hospital from January 2007 to
December 2009. For this study, 70 patients with ITP were
enrolled who had attended pediatric hematology clinics,
visited emergency departments, or been referred from
other hospitals. For the control group, blood was collected
from January 2007 to December 2009 from 70 healthy
children (37 boys and 33 girls; mean age, 4.3  3.8 years)
who were in our vaccine study or were brought to our
pediatric hematology clinic for blood typing. These children
had no underlying diseases, and a hemogram showed no
evidence of thrombocytopenia.
The diagnosis of primary ITP was established on the basis
of history, physical examination, and a laboratory result
showing isolated thrombocytopenia (peripheral blood
platelet count <100,000/mm3) in the absence of other
disorders that may be associated with thrombocytopenia.12
If a patient had atypical features or was not responding to
therapy, a bone marrow aspirate was performed to exclude
other diseases that result in thrombocytopenia. The age
and season of onset, sex, antecedent of preceding illness
(API), initial platelet count at diagnosis, treatment choice
and response, and disease duration of the patients were
also evaluated. API was defined as the occurrence of viral
infection or immunization within 4 weeks prior to pre-
senting with bleeding manifestations.13 This study was
approved by the Institutional Review Board of National
Taiwan University Hospital and Shin Kong Wu Ho-Su Memo-
rial Hospital. Informed written consent was obtained from
the parents of each participant.
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duration
Corticosteroids (predominantly prednisolone) and intrave-
nous immunoglobulins (IVIGs) were the major medical
treatments in our study patients. Splenectomywas indicated
for severe acute ITP with acute life-threatening hemorrhage
or for older children ( 4 years) with severe ITP that had
lasted >1 year (chronic ITP) and whose symptoms were not
easily controlled with medical therapy. Prednisolone was
administered at a dose of 2 mg/kg/day (maximum 60 mg/
day) for 21e28 days or until an increase in the platelet count
to >20,000/mm3 was achieved. IVIG was administered at
a dose of 1 g/kg/day for 2 days. Each patient was assessed
for his or her response to treatment. The timing of moni-
toring of platelet counts and response assessment was
determined by the expected kinetics of platelet increase
after each treatment.12 Therefore, treatment response was
monitored on Day 28 of corticosteroid treatment and on Day
3 of IVIG administration. The duration of follow-up was  12
months from diagnosis. A good response was defined as an
increase in the platelet count of 50,000/mm3. A poor
response was defined as an increase in the platelet count of
<50,000/mm3. Based on the International Working Group
consensus definitions for disease duration, acute ITP (i.e.,
newly diagnosed ITP) indicates that the platelet count
returned to normal (>150,000/mm3) within 3 months from
diagnosis. Persistent ITP refers to patients who did not
achieve spontaneous remission or did not maintain their
response after stopping treatment between 3 and 12 months
from diagnosis. Chronic ITP is reserved for patients with ITP
lasting for more than 12 months.12
HLA DNA typing with PCR and sequence-specific
oligonucleotides
HLA DNA typing was performed with Lifecodes HLA-SSO
(sequence-specific oligonucleotides) typing kits (Tepnel,
Stamford, CT, USA). Genomic DNA from patients and
controls was isolated at a concentration of 10e200 ng/ml.
DNA was amplified with Taq polymerase and biotinylated
primers supplied with the kit. The reaction mixture was
subjected to eight cycles of denaturation for 30 seconds
at 95C, annealing for 45 seconds at 60C, and extension
for 45 seconds at 72C. Another 32 cycles were performed
that consisted of denaturation for 30 seconds at 95C,
annealing for 45 seconds at 63C, and extension for 45
seconds at 72C. After amplification, the amplified DNAs
were subjected to the following incubation conditions for
hybridization: 97C for 5 minutes, 47C for 30 minutes, and
56C for 10 minutes. During hybridization, streptavidin-
phycoerythrin was added for labeling. The HLA DNA was
then typed and analyzed with a Luminex instrument
(Luminex Corporation, Austin, TX, USA).
Statistical analysis
Statistical analyses were performed using SAS software,
version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Associa-
tions between categorical variables were analyzed with
a chi-square test or Fisher’s exact test, whereas the meansof continuous variables were compared with a two-sample
t-test or a Wilcoxon rank-sum test.
To analysis the HLA genotype distributions in control and
ITP groups and to investigate the predictive values of age
of onset, gender, season of onset, API, the initial platelet
count, and HLA genotype on the treatment responses and
disease duration for patients with ITP, we conducted
regression analyses. First, we carried out a logistic regres-
sion analysis with only the first episode for each patient.
Then we fitted a marginal logistic regression model using
the generalized estimating equations (GEE) method for all
the observed episodes for each patient. The GEE method
helped us obtain consistent estimates of the standard
errors for the estimated regression coefficients to make
consistent inferences about the regression coefficients
from the correlated data based on the correct p values. In
the GEE analysis, if the first-order autocorrelation structure
fits the repeated measures data well, the model-based
estimates of the standard errors for the estimated regres-
sion coefficients are used. Otherwise, the empirical stan-
dard error estimates are reported.
The goal of regression analysis is to find one or a few
parsimonious regression models that fit the observed data
well. To ensure the quality of the analysis results, basic
model-fitting techniques for (1) variable selection, (2)
goodness-of-fit (GOF) assessment, and (3) regression diag-
nostics were used in our regression analyses. Specifically,
the stepwise variable selection procedure (with iterations
between the forward and backward steps) was applied to
obtain a candidate final regression model. All the relevant
univariate co-variates (both significant and nonsignificant
ones) were initially included on the variable list, and the
significance levels for entry and for stay were set to 0.15 or
larger. Then, with the aid of substantive knowledge, the best
final regression model was identified manually by reducing
the significance levels to 0.05. Any discrepancy between
the results of the univariate analysis and multivariate
analysis was likely due to confounding effects of uncontrolled
co-variates in the univariate analysis. Both the GOFmeasures
(including the percentage of concordant pairs, estimated
area under the receiver operating characteristic curve, and
adjusted generalized R2) and the GOF tests (including the
deviance GOF test, Pearson chi-square GOF test, and
Hosmer-Lemeshow GOF test) were examined to assess the
GOF of the fitted logistic regressionmodel. Because the value
of the adjusted generalized R2 for the logistic regression
model is usually low, the larger p values of the deviance GOF
test, Pearson chi-square GOF test, and Hosmer-Lemeshow
GOF test indicate better fits. In addition, the statistical
tools for regression diagnostics such as residual analysis,
detection of influential cases, and a check for multi-
collinearity were used to discover model or data problems.
Results
Demographic and clinical characteristics of
pediatric patients with ITP
Among the 70 patients with ITP who were included in this
study, 33 were males and 37 were females. The mean age
at onset was 6.0  3.9 years, with 23 patients (32.9%) who
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apparent proclivity of season of onset for the occurrence
of ITP (DecembereFebruary, 25.7%; MarcheMay, 22.9%;
JuneeAugust, 24.3%; and SeptembereNovember, 27.1%). A
total of 42 patients (60%) had a history of API. The mean
platelet count at diagnosis was 14,266  16,156/mm3, with
54 patients (77%) whose initial platelet count was <
20,000/mm3. A total of 67 patients (95.7%) had received
various treatments, predominantly corticosteroids (47
cases, 67.1%) or IVIG (43 cases, 61.4%). Thirty patients
(42.3%) had received two or more types of treatment (data
not shown). Four patients (5.7%) had undergone a splenec-
tomy for the treatment of ITP (Table 1). In addition, 18 of
the 47 patients (38%) who had ever received corticosteroids
showed a good response, and 20 of the 43 patients (47%)
who had ever received IVIG showed a good response. After
a follow-up period of at least 12 months from diagnosis, 32
patients had acute ITP (45.7%), eight patients had persis-
tent ITP (11.4%), and 30 patients had chronic ITP (42.9%).
Analysis of HLA genotype distributions in control
and ITP groups
We analyzed the differential distribution of HLA class I and
II genotypes between the ITP patient population and theTable 1 Demographic and clinical characteristics of the contro
Characteristics Con
Number of patients 70
Sex ratio (male:female) 37:
Age at onset, y
Mean  SD 4.3
<8 y 55
8 y 15
Season of onset
DecembereFebruary
MarcheMay
JuneeAugust
SeptembereNovember
API
Initial platelet count
Mean  SD (per mm3)
<20,000/mm3
20,000/mm3
Medical treatment
Any
Corticosteroids (predominantly prednisolone)
IVIG
Danazol
Azathioprine
Quinidine
Vincristine
Mycophenolate mofetil
Patients progressing to requiring splenectomy
API Z antecedent of preceding illness; HLA Z human leukocyte a
immunoglobulin; SD Z standard deviation.
a Continuous variables were tested by the Wilcoxon rank-sum test, wh
b The value here indicates the mean age of the control participantscontrol population (Table 2). Multivariate analysis showed
that the frequency of heterozygous HLA-A11 was signifi-
cantly decreased in the ITP group [odds ratio (OR) Z
0.396, p Z 0.0160] compared with the control group
(Table 3). The presence of the HLA-Cw1 allele was also
decreased in the ITP group (OR Z 0.348, p Z 0.0089). By
contrast, the frequency of heterozygous HLA-DQ5 was
significantly increased in the ITP group (OR Z 3.838,
p Z 0.0057). None of the other alleles were differentially
distributed between the control and ITP groups.
Analysis of demographic and clinical parameters
and HLA genotypes with respect to ITP treatment
responses
When analyzing demographic and clinical parameters
among patients with ITP, we found that individuals with an
older age of onset were at higher risk for a poor response to
either or both treatments (p < 0.001). These results are
shown in Table 4. When choosing the cut-off age at 8 years,
we found that patients whose age of onset was  8 years
were at higher risk for a poor response to either or both
treatments (pZ 0.012). Patients with API were more likely
to show a good response to either or both treatments
(p Z 0.004). When analyzing demographic and clinicall individuals and patients with ITP.
trol ITP p valuea
70
33 33:37 0.612
 3.8b 6.0  3.9 0.018
(78.6%) 47 (67.1%) 0.183
(21.4%) 23 (32.9%)
18 (25.7%)
16 (22.9%)
17 (24.3%)
19 (27.1%)
42 (60%)
14,266  16,156
54 (77%)
16 (23%)
67 (95.7%)
47 (67.1%)
43 (61.4%)
14 (20%)
3 (4.3%)
2 (2.9%)
1 (1.4%)
1 (1.4%)
4 (5.7%)
ntigen; ITP Z immune thrombocytopenia; IVIG Z intravenous
ereas categorical variables were tested by the Fisher’s exact test.
.
Table 2 HLA classes I and II genotypes of the control and
ITP groups.
Genotype Gene dose n (%) p valuea
Control
group
(n Z 70)
ITP group
(n Z 70)
HLA-A
A2 Heterozygous 32 (45.7) 30 (42.9) 0.86
Homozygous 6 (8.6) 8 (11.4)
A11 Heterozygous 34 (48.6) 23 (32.9) 0.05
Homozygous 5 (7.1) 13 (18.6)
A33 Heterozygous 9 (12.9) 6 (8.6) 0.79
Homozygous 1 (1.4) 1 (1.4)
A24 Heterozygous 25 (35.7) 14 (20) 0.06
Homozygous 0 (0) 1 (1.4)
A26 Heterozygous 4 (5.7) 4 (5.7) >0.99
Homozygous 0 (0) 0 (0)
A29 Heterozygous 0 (0) 4 (5.7) 0.12
Homozygous 0 (0) 0 (0)
HLA-B
B13 Heterozygous 15 (21.4) 13 (18.6) 0.68
Homozygous 1 (1.4) 0 (0)
B15 Heterozygous 11 (15.7) 12 (17.1) >0.99
Homozygous 1 (1.4) 1 (1.4)
B38 Heterozygous 7 (10) 8 (11.4) >0.99
Homozygous 1 (1.4) 1 (1.4)
B40 Heterozygous 20 (28.6) 26 (37.1) 0.64
Homozygous 4 (5.7) 3 (4.3)
B51 Heterozygous 8 (11.4) 9 (12.9) 0.80
Homozygous 0 (0) 1 (1.4)
B58 Heterozygous 10 (14.3) 12 (17.1) 0.82
Homozygous 1 (1.4) 0 (0)
B46 Heterozygous 16 (22.9) 8 (11.4) 0.20
Homozygous 4 (5.7) 3 (4.3)
B27 Heterozygous 4 (5.7) 9 (12.9) 0.24
Homozygous 0 (0) 0 (0)
B55 Heterozygous 6 (8.6) 4 (5.7) 0.74
Homozygous 0 (0) 0 (0)
B39 Heterozygous 4 (5.7) 6 (8.6) 0.74
Homozygous 0 (0) 0 (0)
B52 Heterozygous 0 (0) 2 (2.9) 0.50
Homozygous 0 (0) 0 (0)
B7 Heterozygous 1 (1.4) 4 (5.7) 0.37
Homozygous 0 (0) 0 (0)
HLA-C
Cw3 Heterozygous 24 (34.3) 24 (34.3) >0.99
Homozygous 8 (11.4) 7 (10)
Cw7 Heterozygous 29 (41.4) 25 (35.7) 0.70
Homozygous 1 (1.4) 2 (2.9)
Cw8 Heterozygous 11 (15.7) 8 (11.4) 0.38
Homozygous 0 (0) 2 (2.9)
Cw12 Heterozygous 9 (12.9) 11 (15.7) 0.64
Homozygous 0 (0) 1 (1.4)
Cw15 Heterozygous 4 (5.7) 11 (15.7) 0.10
Homozygous 0 (0) 0 (0)
Cw4 Heterozygous 5 (7.1) 5 (7.1) >0.99
Homozygous 0 (0) 0 (0)
Cw1 Heterozygous 23 (32.9) 15 (21.4) 0.15
Homozygous 6 (8.6) 3 (4.3)
Table 2 (continued )
Genotype Gene dose n (%) p valuea
Control
group
(n Z 70)
ITP group
(n Z 70)
Cw14 Heterozygous 2 (2.9) 6 (8.6) 0.27
Homozygous 0 (0) 0 (0)
HLA-DQ
DQ2 Heterozygous 12 (17.1) 8 (11.4) 0.28
Homozygous 0 (0) 2 (2.9)
DQ3 Heterozygous 35 (50) 35 (50) 0.49
Homozygous 15 (21.4) 20 (28.6)
DQ5 Heterozygous 12 (17.1) 22 (31.4) 0.02
Homozygous 4 (5.7) 0 (0)
DQ6 Heterozygous 27 (38.6) 24 (34.3) 0.38
Homozygous 2 (2.9) 0 (0)
DQ4 Heterozygous 10 (14.3) 7 (10) 0.61
Homozygous 0 (0) 0 (0)
HLA-DRB1
DRB1*03 Heterozygous 8 (11.4) 8 (11.4) >0.99
Homozygous 0 (0) 0 (0)
DRB1*04 Heterozygous 18 (25.7) 19 (27.1) >0.99
Homozygous 0 (0) 0 (0)
DRB1*09 Heterozygous 19 (27.1) 15 (21.4) 0.52
Homozygous 1 (1.4) 3 (4.3)
DRB1*11 Heterozygous 10 (14.3) 13 (18.6) 0.62
Homozygous 1 (1.4) 2 (2.9)
DRB1*12 Heterozygous 14 (20) 15 (21.4) 0.90
Homozygous 2 (2.9) 3 (4.3)
DRB1*15 Heterozygous 16 (22.9) 16 (22.9) >0.99
Homozygous 1 (1.4) 1 (1.4)
DRB1*16 Heterozygous 9 (12.9) 10 (14.3) >0.99
Homozygous 1 (1.4) 0 (0)
DRB1*08 Heterozygous 14 (20) 10 (14.3) 0.75
Homozygous 1 (1.4) 1 (1.4)
DRB1*07 Heterozygous 4 (5.7) 2 (2.9) 0.68
Homozygous 0 (0) 0 (0)
DRB1*13 Heterozygous 4 (5.7) 5 (7.1) >0.99
Homozygous 0 (0) 0 (0)
HLA-DRB3 Heterozygous 39 (55.7) 38 (54.3) >0.99
Homozygous 0 (0) 0 (0)
HLA-DRB4 Heterozygous 31 (44.3) 31 (44.3) >0.99
Homozygous 0 (0) 0 (0)
HLA-DRB5 Heterozygous 25 (35.7) 21 (30) 0.59
Homozygous 0 (0) 0 (0)
HLAZhumanleukocyteantigen; ITPZ immunethrombocytopenia.
a Fisher’s exact test.
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with ITP by multivariate analysis, we found that an older
age of onset was a predictor for poor response to either or
both treatments (OR Z 1.3476, p Z 0.0010). These results
are shown in Table 5. The presence of API was a predictor
for good response to treatment (ORZ 0.1594, pZ 0.0380).
In addition, patients with ITP who responded poorly to
either or both treatments revealed an increase in the
frequency of HLA-DQ3 (OR Z 15.5428, p Z 0.0024) and
Table 3 Multivariate analysis of demographic parameters and HLA alleles for the occurrence of ITP.a
Regression
coefficient
Standard
error
Wald p value Odds
ratio
95% confidence
interval
(Intercept) 0.3740 0.3416 1.1984 0.2736
HLA-A11 (heterozygous) 0.9251 0.3839 5.8077 0.0160 0.396 0.187e0.841
HLA-Cw1 1.0547 0.4031 6.8446 0.0089 0.348 0.158e0.768
HLA-DQ5 (heterozygous) 1.3448 0.4861 7.6549 0.0057 3.838 1.480e9.949
HLA Z human leukocyte antigen; ITP Z immune thrombocytopenia.
a Multiple logistic regression model: n Z 140, adjusted generalized R2 Z 0.161, estimated area under the receiver operating char-
acteristic curve Z 0.698, and the Hosmer and Lemeshow goodness-of-fit Chi-square test p Z 0.564 > 0.05 (df Z 6).
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p Z 0.0095). Furthermore, patients with ITP with HLA-
DRB1*11 or -DRB1*15 were more likely to respond poorly
to corticosteroids compared with their response to IVIG
(OR Z 56.1135, p Z 0.0446; OR Z 144.4028, p Z 0.0008,
respectively). By contrast, patients who were heterozygous
for HLA-A11 were more likely to have a better response
to corticosteroids than to IVIG (ORZ 0.0711, p Z 0.0338),
as were patients who harbored the HLA-A24 allele
(OR Z 0.0009, p Z 0.0014). Therefore, API, age of onset,
and particular HLA alleles exhibited strong correlations
with treatment responses in this population.Table 4 Demographic and clinical characteristics in relation to t
Characteristics Treatment response p
Good Poor
Number 38c 52c
Sex ratio (male/female) 18:20 27:25 0.
Age at onset, y
Mean  SD 4.0  3.3 7.7  5.3 <0
<8 y 31 (81.6%) 29 (55.8%) 0.
8 y 7 (18.4%) 23 (44.2%)
Season of onset
DecembereFebruary 11 (28.9%) 12 (23.1%) 0.
MarcheMay 7 (18.4%) 12 (23.1%) 0.
JuneeAugust 9 (23.7%) 14 (26.9%) 0.
SeptembereNovember 11 (28.9%) 14 (26.9%) 0.
API 29 (76.3%) 25 (48.1%) 0.
Initial platelet count
Mean  SD (per mm3) 12,710  6,258 14,690  14,924 0.
<20,000/mm3 31 (81.6%) 42 (80.8%) 0.
20,000/mm3 7 (18.4%) 10 (19.2%)
Medical treatment 0.
Corticosteroids 18 (47.4%) 29 (55.8%)
IVIG 20 (52.6%) 23 (44.2%)
APIZ antecedent of preceding illness; GEEZ generalized estimating
immunoglobulin; SD Z standard deviation.
a Both continuous and categorical variables were tested with a log
correlation structure was specified, and a robust variance estimate w
b Continuous variables were tested by the Wilcoxon rank-sum test,
test.
c These figures are the number of treatments. Thirty patients recei
d These figures are the number of patients who had ever received c
e These figures are the number of patients who had ever received IAnalysis of demographic and clinical parameters
and HLA genotypes in patients with persistent or
chronic ITP
When analyzing demographic and clinical parameters
among patients with persistent or chronic ITP, we found
that patients with an older age of onset and absence of
API were more likely to develop persistent or chronic ITP
(p Z 0.004 and p Z 0.001, respectively). See Table 4 for
more detail. When analyzing demographic and clinical
parameters and HLA classes I and II alleles among patients
with persistent or chronic ITP by multivariate analysis, wereatment response and disease duration for patients with ITP.
valuea Disease duration p
valuebAcute ITP Persistent or chronic ITP
32 38
760 16:16 17:21 0.810
.001 4.2  3.6 7.5  5.1 0.004
012 25 (78.1%) 22 (57.9%) 0.727
7 (21.9%) 16 (42.1%)
612 9 (28.1%) 9 (23.7%) 0.323
978 6 (18.7%) 11 (28.9%) 0.719
571 7 (21.9%) 10 (26.3%) 0.295
488 10 (31.3%) 8 (21.1%) 0.375
004 26 (81.3%) 16 (42.1%) 0.001
516 12,840  17,688 14,870  13,826 0.125
855 26 (81.3%) 29 (76.3%) 0.552
6 (18.7%) 9 (23.7%)
938
11 (34.4%)d 36 (94.7%)d <0.001
22 (68.8%)e 21 (55.3%)e 0.317
equation; ITPZ immune thrombocytopenia; IVIGZ intravenous
istic regression model using the GEE method. An exchangeable
as used in the GEE analysis.
whereas categorical variables were tested by the Fisher’s exact
ved two treatments because one treatment had failed.
orticosteroids treatment.
VIG treatment.
Table 5 Multivariate analysis of the predictors of a poor response.a
Covariate Regression
coefficient
Standard error Wald p value Odds ratio 95% confidence
interval
(Intercept) 4.3793 1.5171 8.3324 0.0039
Poor response to either
or both treatments
Age of onset 0.2983 0.0905 10.8759 0.0010 1.3476 1.1286e1.6090
API 1.8366 0.8854 4.3030 0.0380 0.1594 0.0281e0.9037
HLA-DRB1*08 2.9394 1.1330 6.7302 0.0095 0.0529 0.0057e0.4874
HLA-DQ3 2.7436 0.9044 9.2036 0.0024 15.5428 2.6406e91.7431
Likelihood of responding
more poorly to
corticosteroids than IVIG
HLA-A11 (heterozygous) 2.6433 1.2454 4.5047 0.0338 0.0711 0.0062e0.8169
HLA-A24 7.0298 2.2007 10.2037 0.0014 0.0009 0.0001e0.0661
HLA-DRB1*11 4.0274 2.0056 4.0323 0.0446 56.1135 1.1012e2859.3960
HLA-DRB1*15 4.9726 1.4881 11.1665 0.0008 144.4028 7.8144e2668.4180
API Z antecedent of preceding illness; GEE Z generalized estimating equation; HLA Z human leukocyte antigen; IVIG Z intravenous
immunoglobulin.
a Multiple logistic regression model using the GEE method: nZ 67 (90 observations), adjusted generalized R2Z 0.523 > 0.3, estimated
area under the receiver operating characteristic curve Z 0.9236 > 0.7, and the Hosmer and Lemeshow goodness-of-fit F test
p Z 0.7487 > 0.05 (df Z 9,80).
376 W.-L. Ho et al.found a positive association between HLA-A11 homozy-
gosity and the development of persistent or chronic ITP
(OR Z 6.3165, p Z 0.0479). These results are shown in
Table 6. The presence of HLA-DRB1*08 was, however,
negatively correlated with the development of persistent
or chronic ITP (OR Z 0.1729, p Z 0.0657). In addition,
patients with API were less likely to develop persistent or
chronic ITP (OR Z 0.2493, p Z 0.0241), whereas patients
with an older age of onset were more likely to develop
persistent or chronic ITP (OR Z1.1664, p Z 0.0379).Discussion
We characterized children with ITP who were seen at two
major referral centers in Taiwan. Our goal was to delineate
demographic factors, laboratory parameters, and HLA
genotypes to better understand the characteristics of
childhood ITP and to explore the relationships between
these factors and the natural history and treatment
response of this disorder. We observed that there was no
predisposition to the occurrence of childhood ITP basedTable 6 Multivariate analysis of the predictors for persistent o
Regression
coefficient
Standard
error
(Intercept) 1.5992 1.1657
Age of onset 0.1539 0.0741
API 1.3890 0.6158
HLA-A11 (homozygous) 1.8432 0.9318
HLA-DRB1*08 1.7552 0.9535
API Z antecedent of preceding illness; HLA Z human leukocyte anti
a Multiple logistic regression model with the stepwise variable select
area under the receiver operating characteristic curveZ 0.809, and t
(df Z 9,60).on gender or season of onset. There were, however, twice
as many patients whose age of onset was < 8 years as
compared with those whose age of onset was  8 years,
suggesting an age predisposition for this disorder. These
findings are similar to those in previous studies.14,15
Various autoimmune diseases are associated with
particular HLA class I alleles, class II alleles, or both.
Therefore, several groups previously investigated the role
of HLA class I and HLA-DR in ITP, albeit with somewhat
inconsistent results.9,10,16e18 Few pediatric studies on this
issue have been performed. Intriguingly, Olsson and
colleagues19 found increased expression of several cyto-
toxic genes in patients with ITP as compared with controls.
As apparent compensation for this increased cytotoxicity,
they also found increased expression of the KIR family of
receptors on CD3þ T cells, including KIR3DL1, KIR3DL2, and
KIR2DL3, in patients with ITP in remission (i.e., acute ITP)
as compared with controls and with patients with active
ITP. Later, they reported20,21 that apoptotic resistance of
activated T lymphocytes in patients with active ITP may
lead to defective clearance of autoreactive T lymphocytes
through activation-induced cell death, which might causer chronic ITP.a
Wald p value Odds
ratio
95% confidence
interval
1.3718 0.1701
2.0755 0.0379 1.1664 1.018e1.368
2.2556 0.0241 0.2493 0.070e0.810
1.9781 0.0479 6.3165 1.207e53.662
1.8407 0.0657 0.1729 0.020e0.9653
gen; ITP Z immune thrombocytopenia.
ion method: nZ 70, adjusted generalized R2Z 0.373, estimated
he Hosmer and Lemeshow goodness-of-fit F test pZ 0.171 > 0.05
MHC and pediatric ITP 377a continued destruction of platelets (i.e., persistent or
chronic ITP). HLA-A11 and HLA-Cw1, which are HLA class I
molecules, have long been known to be associated with
specific biological functions. HLA-A11 is the natural ligand
for the inhibitory KIR3DL2 receptor,22 whereas HLA-Cw1,
a group 1 HLA-C molecule, is the natural ligand for
KIR2DL2 and KIR2DL3 receptors on NK cells and T cells.23
KIRs downregulate cytotoxic T-lymphocyte and NK-cell
responses by binding to MHC class I molecules, thereby
preventing lysis of target cells. Several epitopes recognized
by cytotoxic T lymphocytes are HLA-A11 restricted,
including peptides derived from human papillomavirus,24
hepatitis C virus,25,26 human immunodeficiency virus,27e29
and Epstein-Barr virus.30e32 HLA-DQ5 is associated with
a number of autoimmune disorders, such as myasthenia
gravis,33 juvenile rheumatoid arthritis,34e36 and other
diseases.37,38
Our study results showed that HLA-A11 heterozygosity
and the presence of the HLA-Cw1 allele seemed to be
protective factors for the development of childhood ITP,
whereas HLA-DQ5 heterozygosity seemed to be a risk factor
for the development of this disorder. Moreover, in contrast
to the apparent protective effects and the tendency of
a better response to corticosteroids that are conferred by
HLA-A11 heterozygosity, in the subgroup analysis of HLA
genotypes for patients progressing to persistent or chronic
ITP, we found a positive association between HLA-A11
homozygosity and the development of persistent or
chronic ITP (Table 6). Whether the balance (or ratio)
between the persistent existence of autoreactive T
lymphocytes that is due to apoptotic resistance and the
inhibitory effects of KIRs on NK cells and T cells contributed
to the opposing results of HLA-A11 homozygosity and
heterozygosity needs further investigation. These findings
do, however, suggest a possible mechanism for the HLA bias
we found in this population of patients with ITP. Thus, the
relationship between particular HLA class I alleles and the
mechanism of cytotoxicity and childhood ITP warrants
further study in the near future.
In contrast to outcomes associated with two copies of
HLA-A11, the presence of HLA-DRB1*08 was less likely to
show a poor response to treatment (Table 5) and to
develop persistent or chronic ITP (Table 6). HLA-DRB1*08,
an HLA class II molecule, is associated with several
diseases in particular populations, including primary biliary
cirrhosis,39e42 ulcerative colitis,43 and ankylosing spondy-
litis.44,45 Additional investigation is needed to determine
the role that HLA-DRB1*08 plays in the pathogenesis of
pediatric ITP in Taiwan.
In this study, we found that particular HLA class I allele
patterns were associated with a better response to corti-
costeroids than IVIG, including heterozygosity for HLA-A11
and harboring the HLA-A24 allele. Particularly, HLA class II
alleles, such as HLA-DRB1*11 or HLA-DRB1*15, were more
likely to be related to a poor response to corticosteroids
than to IVIG. IVIG may exert its main action by blocking
Fcg receptors or neutralizing autoantibodies by idiotypee
anti-idiotype interactions.46 We suggest that patients with
ITP who harbor the particular HLA class II alleles described
above are more likely to experience a disease course with
a greater likelihood of Th2 bias or autoantibody production.
The utility of corticosteroids does, however, suggest thatdisruption of T-cell regulation47 and inhibition of phagocy-
tosis, which increases the lifespan of platelets,6 are critical
for ITP. It remains to be determined whether patients
with ITP who harbor the particular HLA class I alleles
described above are more likely to experience a disease
course with a greater likelihood of Th1 bias or cell-
mediated cytotoxicity.
Childhood ITP is most commonly associated with
a preceding viral illness, and the mechanism of “molecular
mimicry” along with an inflammatory state may play a crit-
ical role. ITPmay also occur after vaccination against MMR,48
pneumococcus, Haemophilus influenzae B, diphtheria-
tetanus-pertussis (DTP), hepatitis B virus, or varicella-zoster
virus (VZV).49 In this study, we found that patients with
API and with a younger age of onset were more likely to
experience a better treatment response and shorter course
of ITP, which is in agreement with the results reported by
Donato and colleagues.13 and France and others.48
Analysis of the relationship between the HLA-A11 allele
and the duration of ITP revealed that two copies of A11
predisposed patients to persistent and chronic ITP. HLA-A11
heterozygosity, in contrast, was a protective factor for
the development of childhood ITP and also predisposed
patients to respond better to corticosteroids than to IVIG.
The Taiwanese population is highly positive for HLA-A1150;
whether this allele is a susceptibility gene for a particular
virus or other pathogens in the pediatric population, as well
as the identification of its role in childhood ITP, warrants
further investigation.
There are several caveats intrinsic to small-group
population studies that require acknowledgment when
attempting to apply findings to the population as a whole.
First, it is possible that a population of children with ITP
who were referred to a tertiary university hospital referral
center is inherently more likely to respond poorly to ther-
apies and to have a persistent or chronic form of the
disease. In addition, the response rate to various therapies
may be affected by the chosen cut-off point for the change
in platelet counts following cessation of therapy (in our
study, it was set at 50,000/mm3). Although some HLA
class I and class II alleles were significantly associated with
childhood ITP in our study, additional combinations of
predisposing gene variants and non-HLA genetic factors are
likely to contribute to the development and disease course
of ITP and to the treatment response of individual patients
with ITP.
Furthermore, our findings are statistically significant
within the population tested, but the power of an associ-
ation study depends critically on the sample size. This case-
control study made several important discoveries and
advances, but its retrospective and nonrandomized nature
inevitably limited the strength of the conclusions. Yet,
based on these findings, prospective randomized controlled
trials can be conducted in larger groups of patients to
provide further insight into the immunogenetic suscepti-
bility and clinical correlations of childhood ITP.Acknowledgment
This study was supported in part by a research grant (SKH-
8302-97-DR-22) from the Shin Kong Wu Ho-Su Memorial
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